


Ask a doctor about a prescription for TREVICTA 350 MG PROLONGED-RELEASE INJECTABLE SUSPENSION
Package Leaflet: Information for the User
TREVICTA 175 mg prolonged-release injectable suspension
TREVICTA 263 mg prolonged-release injectable suspension
TREVICTA 350 mg prolonged-release injectable suspension
TREVICTA 525 mg prolonged-release injectable suspension
paliperidone
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
Contents of the pack
TREVICTA contains the active substance paliperidone, which belongs to a class of medicines called antipsychotics and is used as maintenance treatment to control the symptoms of schizophrenia in adult patients.
If you have responded well to treatment with paliperidone palmitate injectable suspension given once a month, your doctor may decide to start treatment with TREVICTA.
Schizophrenia is a disorder with "positive" and "negative" symptoms. Positive means an excess of symptoms that are normally not present. For example, a person with schizophrenia may hear voices or see things that do not exist (called hallucinations), have false beliefs (called delusions), or have an abnormal distrust of others. Negative refers to the lack of behaviors or feelings that are normally present. For example, a person with schizophrenia may withdraw into themselves and not respond to any emotional stimulus or may have trouble speaking in a clear and logical manner. People with this disorder may also feel depressed, anxious, guilty, or tense.
TREVICTA can relieve the symptoms of your illness and reduce the likelihood of them coming back.
Do not use TREVICTA
Warnings and precautions
Talk to your doctor, pharmacist, or nurse before you start using TREVICTA.
This medicine has not been studied in elderly patients with dementia. However, elderly patients with dementia who are being treated with other similar medicines may have an increased risk of stroke or death (see section 4).
All medicines can cause side effects and some of the side effects of this medicine may worsen the symptoms of other illnesses. For this reason, it is important that you discuss with your doctor any of the following illnesses that may worsen during treatment with this medicine.
If you are in any of these situations, talk to your doctor, as it may be necessary to adjust the dose or monitor your condition for some time.
Given that it has been rarely observed that patients receiving this medicine have a dangerously low number of a certain type of white blood cell responsible for fighting infections in the blood, the doctor may decide to perform white blood cell counts.
Even if you have previously tolerated oral paliperidone or risperidone, rare allergic reactions may occur after receiving TREVICTA injections. Seek medical help immediately if you experience a skin rash, swelling of the throat, itching, or breathing problems, as these may be signs of a severe allergic reaction.
This medicine may cause weight gain. Significant weight gain could be harmful to your health. Your doctor will regularly check your body weight.
Since diabetes mellitus or worsening of pre-existing diabetes mellitus has been observed in some patients using this medicine, the doctor should monitor for possible signs of high blood sugar. In patients with pre-existing diabetes mellitus, blood sugar levels should be regularly checked.
Since this medicine can reduce the vomiting reflex, there is a possibility that it may mask the normal response of the body to the ingestion of toxic substances or other illnesses.
During eye surgery for cataracts, the pupil (the black circle in the center of the eye) may not increase in size as needed. Additionally, the iris (the colored part of the eye) may become flaccid during surgery, which can cause eye damage. If you are planning to have eye surgery, make sure to inform your ophthalmologist that you are using this medicine.
Children and adolescents
Do not use this medicine in children and adolescents under 18 years of age. Its safety and efficacy in these patients are not known.
Other medicines and TREVICTA
Tell your doctor if you are taking, have recently taken, or might take any other medicines.
If you take this medicine with carbamazepine (an antiepileptic and mood stabilizer), you may need to adjust the dose of this medicine.
Since this medicine acts mainly on the brain, the use of other medicines with brain action may exaggerate side effects such as drowsiness or other brain effects, such as other psychiatric medicines, opioids, antihistamines, and sleeping medicines.
Because this medicine can lower blood pressure, caution should be exercised when combining it with other medicines that lower blood pressure.
This medicine may reduce the effect of medicines used for Parkinson's disease and restless legs syndrome (e.g., levodopa).
This medicine may cause an abnormality in the electrocardiogram (ECG) that indicates that the electrical impulses take longer to reach a specific part of the heart (known as "prolongation of the QT interval"). Among the medicines that have this effect are some medicines used to regulate heart rhythm or treat infections, as well as other antipsychotics.
If you have a history of seizures, this medicine may increase the likelihood of having them again. Other medicines that have this effect include some medicines used to treat depression or infections and other antipsychotics.
TREVICTA should be used with caution with medicines that increase the activity of the central nervous system (psychostimulants such as methylphenidate).
TREVICTA with alcohol
Alcohol should be avoided.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before using this medicine. You should not use this medicine during pregnancy unless you have discussed it with your doctor. In newborn babies of mothers who have received paliperidone in the last trimester (the last three months of pregnancy), the following symptoms may appear: tremors, stiffness or muscle weakness, drowsiness, agitation, breathing problems, or difficulty feeding. If your child shows any of these symptoms, seek medical attention for your child.
This medicine can pass from mother to child through breast milk and be harmful to the child. For this reason, you should not breastfeed while using this medicine.
Driving and using machines
During treatment with this medicine, dizziness, extreme fatigue, and vision problems (see section 4) may occur. These effects should be taken into account in cases where maximum attention is required, for example, when driving vehicles or operating machinery.
TREVICTA contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per dose, which is essentially "sodium-free".
You will be given a TREVICTA injection in the upper arm or buttock once every 3 months.
Depending on your symptoms, the doctor will increase or decrease the amount of medicine you will receive in the next scheduled injection.
Patients with kidney disorders
If you have mild kidney problems, the doctor will determine the appropriate dose of TREVICTA based on the dose of paliperidone palmitate injectable suspension you have been receiving. If you have moderate or severe kidney problems, you should not use this medicine.
Elderly population
If you have reduced kidney function, the doctor will determine the appropriate dose of this medicine.
If you receive more TREVICTA than you should
This medicine will be administered under medical supervision; therefore, it is unlikely that you will receive more than the prescribed amount.
If a patient receives an excessive amount of paliperidone, they may experience the following symptoms: drowsiness or sedation, increased heart rate, low blood pressure, changes in the electrocardiogram (heart electrical recording), or slow and abnormal movements of the face, body, arms, or legs.
If you stop using TREVICTA
If you stop receiving the injections, your schizophrenia symptoms may worsen. You should not stop using this medicine unless your doctor tells you to.
If you have any other questions about the use of this product, ask your doctor or pharmacist.
Like all medicines, this medicine can cause adverse effects, although not all people suffer from them.
Report immediately to your doctor if:
The following adverse effects may appear:
Very common adverse effects: may affect more than 1 in 10 people
Common adverse effects: may affect up to 1 in 10 people
Uncommon adverse effects: may affect up to 1 in 100 patients
Rare adverse effects: may affect up to 1 in 1,000 patients
Frequency not known: cannot be estimated from the available data
Reporting of side effects
If you experience any kind of adverse effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through the national reporting system included in Appendix V. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Do not use this medicine after the expiration date that appears on the packaging. The expiration date is the last day of the month indicated.
This medicine does not require special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of the packaging and medicines that are no longer needed. This will help protect the environment.
TREVICTA Composition
The active ingredient is paliperidone.
Each TREVICTA 175 mg pre-filled syringe contains 273 mg of paliperidone palmitate.
Each TREVICTA 263 mg pre-filled syringe contains 410 mg of paliperidone palmitate.
Each TREVICTA 350 mg pre-filled syringe contains 546 mg of paliperidone palmitate.
Each TREVICTA 525 mg pre-filled syringe contains 819 mg of paliperidone palmitate.
The other components are:
Polysorbate 20
Polyethylene glycol 4000
Citric acid monohydrate
Sodium dihydrogen phosphate monohydrate
Sodium hydroxide (for pH adjustment)
Water for injectable preparations
Product Appearance and Container Contents
TREVICTA is a long-acting injectable suspension, white to off-white in color, presented in a pre-filled syringe that the doctor or nurse will shake vigorously to homogenize the suspension before injecting it.
Each container contains 1 pre-filled syringe and 2 needles.
Only certain package sizes may be marketed.
Marketing Authorization Holder
Janssen-Cilag International NV
Turnhoutseweg 30
B-2340 Beerse
Belgium
Manufacturer
Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse
Belgium
You can request more information about this medication by contacting the local representative of the marketing authorization holder.
| België/Belgique/Belgien Janssen-Cilag NV Tel/Tél: +32 14 64 94 11 | Lietuva UAB “JOHNSON & JOHNSON” Tel: +370 5 278 68 88 | 
| България ”Джонсън & Джонсън” ЕООД Тел.: +359 2 489 94 00 | Luxembourg/Luxemburg Janssen-Cilag NV Tél/Tel: +32 14 64 94 11 | 
| Ceská republika Janssen-Cilag s.r.o. Tel:+420 227 012 227 | Magyarország Janssen-Cilag Kft. Tel.:+36 1 884 2858 | 
| Danmark Janssen-Cilag A/S Tlf: +45 45 94 82 82 | Malta AM MANGION LTD. Tel: +356 2397 6000 | 
| Deutschland Janssen-Cilag GmbH Tel: +49 2137-955-955 | Nederland Janssen-Cilag B.V. Tel: +31 76 711 1111 | 
| Eesti UAB “JOHNSON & JOHNSON” Eesti filiaal Tel.: +372 617 7410 | Norge Janssen-Cilag AS Tlf: +47 24 12 65 00 | 
| Ελλάδα Janssen-Cilag Φαρμακευτικη Α.Ε.Β.Ε Tηλ: +30 210 80 90 000 | Österreich Janssen-Cilag Pharma GmbH Tel: +43 1 610 300 | 
| España Janssen-Cilag, S.A. Tel: +34 91 722 81 00 | Polska Janssen-Cilag Polska Sp. z o.o. Tel.: +48 22 237 60 00 | 
| France Janssen-Cilag Tel: 0 800 25 50 75 / +33 1 55 00 40 03 | Portugal Janssen-Cilag Farmacêutica, Lda. Tel: +351 214 368 600 | 
| Hrvatska Johnson & Johnson S.E. d.o.o. Tel: +385 1 6610 700 | România Johnson & Johnson România SRL Tel: +40 21 207 1800 | 
| Ireland Janssen Sciences Ireland UC Tel: +353 1 800 709 122 | Slovenija Johnson & Johnson d.o.o. Tel: +386 1 401 18 00 | 
| Ísland Janssen-Cilag AB C/o Vistor hf Sími: +354 535 7000 | Slovenská republika Johnson & Johnson s.r.o. Tel: +421 232 408 400 | 
| Italia Janssen-Cilag SpA Tel: +39 02 2510 1 | Suomi/Finland Janssen-Cilag Oy Puh/Tel: +358 207 531 300 | 
| Κύπρος Βαρνάβας Χατζηπαναγής Λτδ Tηλ: +357 22 207 700 | Sverige Janssen-Cilag AB Tel: +46 8 626 50 00 | 
| Latvija UAB “JOHNSON & JOHNSON” filiale Latvija Tel: +371 6789 3561 | United Kingdom Janssen-Cilag Ltd. Tel: +44 1 494 567 444 | 
Date of Last Revision of this Leaflet:
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu/.
Information Reserved for Healthcare Professionals
This information is intended solely for healthcare professionals, who should read it in conjunction with the complete prescribing information (Summary of Product Characteristics).
| 
 | Administer every 3 months | 
| 
 | Shake the syringe vigorously for at least 15 seconds | 
For Intramuscular Injection Only. Do Notadminister by any other route.
Important
Read the complete instructions before using the product. To ensure proper administration of TREVICTA, it is necessary to carefully read these instructions for use.
TREVICTA must be administered by a healthcare professional as a single injection. DO NOTdivide the dose into repeated injections.
TREVICTA is indicated for intramuscular administration only. Inject slowly and deeply into the muscle, avoiding injection into a blood vessel.
Dosage
TREVICTA will be administered once every 3 months.
Preparation
Remove the label from the syringe and attach it to the patient's medical record.
TREVICTA requires more vigorous and prolonged shakingthan the monthly paliperidone palmitate injectable. Shake the syringe vigorously, with the tip pointing upwards, for at least 15 seconds in the 5-minute interval preceding administration(see step 2).
Selection of the Thin-Walled Safety Needle
Thin-walled safety needles are designed for use with TREVICTA. It is essential to use only the needles provided in the TREVICTA package.
Package Contents per Dose


The selection of the needle is determined by the injection site and the patient's weight.
| 
 | 
 | 



Check the Suspension

After shaking the syringe for at least 15 seconds, check the appearance of the suspension in the viewing window.
The suspension should have a uniform appearance and a milky white color.
It is normal for small air bubbles to appear.
Open the Needle Blister Pack and Remove the Cap.

First, open the needle blister pack by peeling back the cover to the middle. Place it on a clean surface.
Then, with the syringe facing upwards, twist the rubber cap to remove it.
Hold the Needle Blister Pack.

Bend back the foil that covers the needle and the plastic tray. Then, firmly grasp the needle sheath, holding it by the blister pack as indicated.
Attach the Needle

With the other hand, hold the syringe by the luer connection and attach the safety needle with a gentle clockwise twist.
Do not removethe blister pack until the syringe and needle are perfectly engaged.
Remove the Needle Cap

Remove the needle cap by pulling it straight off.
Do nottwist the cap, as this may loosen the needle from the syringe.
Eliminate Air Bubbles

Tap the syringe gently with the tip pointing upwards to make any air bubbles rise.
Slowly and carefully, press the plunger upwards to expel the air.

Inject the Dose

Slowly inject the entire contents of the syringeintramuscularly, deeply into the deltoid or gluteus.
Do not administer by any other route.

Protect the Needle

After injection, use your thumb or a flat surface to activate the needle safety mechanism. The needle will be secure when you hear a “click”.
Proper Disposal

Discard the unused syringe and needle in an approved sharps container.

The average price of TREVICTA 350 MG PROLONGED-RELEASE INJECTABLE SUSPENSION in October, 2025 is around 560.29 EUR. Prices may vary depending on the region, pharmacy, and whether a prescription is required. Always check with a local pharmacy or online source for the most accurate information.
The best alternatives with the same active ingredient and therapeutic effect.
Discuss dosage, side effects, interactions, contraindications, and prescription renewal for TREVICTA 350 MG PROLONGED-RELEASE INJECTABLE SUSPENSION – subject to medical assessment and local rules.